1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

 
• By Brenda Sandburg

Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.

The Federal Trade Commission's global settlement with Teva Pharmaceutical Industries Ltd. is a victory for the agency in its campaign to eliminate so-called pay-for-delay deals between brand and generic companies that include side deals and commitments by the brand not to launch an authorized generic.

The settlement, announced Feb. 19, resolves claims against Teva in three pending FTC antitrust lawsuits and expands the terms in a 2015 consent decree with Teva's Cephalon Inc. subsidiary resolving Provigil (modafinil) litigation. There is no additional monetary payment beyond the $1.2bn provided in the Cephalon settlement

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

More from Biosimilars & Generics

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.